知镜 Cognispect · 医学文献与研究工作台

Comparative Risk of Respiratory Virus Infections Among Patients with Asthma Treated with Biologic Therapies.

Liao KM, Huang SC, Lao IH, Kuo CY, Hsu WH, Wu JY, Lai CC.
QJM : monthly journal of the Association of Physicians · 2026-08-21 · PMID 42627340

文献摘要

Background Respiratory virus infections are a major cause of morbidity in asthma. Although biologic therapies targeting type 2 inflammation are widely used for severe asthma, their comparative effects on respiratory virus infection risk remain unclear. Methods We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults with asthma who newly initiated benralizumab, omalizumab, dupilumab, or mepolizumab. Using an active comparator, new-user design with 1:1 propensity score matching, we compared benralizumab with each biologic. The primary outcome was a composite of respiratory virus infections (COVID-19, influenza, RSV infection, and viral pneumonia) over three years. Hazard ratios (HRs) were estimated using Cox proportional hazards models. Results After matching, 5,663 benralizumab-omalizumab pairs, 7,075 benralizumab-dupilumab pairs, and 6,492 benralizumab-mepolizumab pairs were included. Benralizumab was associated with a higher risk of composite respiratory virus infection than omalizumab (HR 1.49, 95% CI 1.33-1.66), dupilumab (HR 1.24, 95% CI 1.11-1.39), and mepolizumab (HR 1.24, 95% CI 1.12-1.38; all p Conclusions Benralizumab was associated with a higher risk of respiratory virus infections than omalizumab, dupilumab, and mepolizumab. These findings suggest that profound eosinophil depletion may impair antiviral host defense and should be considered when selecting biologic therapy for patients at increased risk of respiratory viral infections.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。